Information letter on Onsenal® (celecoxibe): Company-led drug withdrawal for the indication "familial adenomatous polyposis" (FAP)
2011.04.08
Active substance: celecoxibe
Important information on the company-led drug withdrawal of Onsenal® (celecoxibe) for the indication familial adenomatous polyposis.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN